Literature DB >> 32080788

Ret Receptor Has Distinct Alterations and Functions in Breast Cancer.

Albana Gattelli1,2, Nancy E Hynes3,4, Ignacio E Schor5,6, Sabrina A Vallone5,7.   

Abstract

Ret receptor tyrosine kinase is a proto-oncogene that participates in development of various cancers. Several independent studies have recently identified Ret as a key player in breast cancer. Although Ret overexpression and function have been under investigation, mainly in estrogen receptor positive breast cancer, a more comprehensive analysis of the impact of recurring Ret alterations in breast cancer is needed. This review consolidates the current knowledge of Ret alterations and their potential effects in breast cancer. We discuss and integrate data on Ret changes in different breast cancer subtypes and potential function in progression, as well as the participation of distinct Ret network signaling partners in these processes. We propose that it will be essential to define a shared molecular feature of tumors with alteration in Ret receptor, be this at the genetic level or via overexpression in order to design effective therapies to target the Ret pathway. Here we review experimental evidence from basic research and pre-clinical studies concentrating on Ret alterations as potential biomarkers for recurrence, and we discuss the possibility that targeting the Ret pathway might in the future become a treatment for breast cancer.

Entities:  

Keywords:  Breast tumors; ER + ; Endocrine resistance; Rearrangements; Ret

Mesh:

Substances:

Year:  2020        PMID: 32080788     DOI: 10.1007/s10911-020-09445-4

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  126 in total

1.  RET Signaling in Prostate Cancer.

Authors:  Kechen Ban; Shu Feng; Longjiang Shao; Michael Ittmann
Journal:  Clin Cancer Res       Date:  2017-05-10       Impact factor: 12.531

2.  Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer.

Authors:  Philip M Spanheimer; Allison W Lorenzen; James P De Andrade; Mikhail V Kulak; Jennifer C Carr; George W Woodfield; Sonia L Sugg; Ronald J Weigel
Journal:  Ann Surg Oncol       Date:  2015-05-14       Impact factor: 5.344

3.  Identification of molecular apocrine breast tumours by microarray analysis.

Authors:  Pierre Farmer; Herve Bonnefoi; Veronique Becette; Michele Tubiana-Hulin; Pierre Fumoleau; Denis Larsimont; Gaetan Macgrogan; Jonas Bergh; David Cameron; Darlene Goldstein; Stephan Duss; Anne-Laure Nicoulaz; Cathrin Brisken; Maryse Fiche; Mauro Delorenzi; Richard Iggo
Journal:  Oncogene       Date:  2005-07-07       Impact factor: 9.867

Review 4.  Structure and physiology of the RET receptor tyrosine kinase.

Authors:  Carlos F Ibáñez
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-02-01       Impact factor: 10.005

Review 5.  Endocrine-responsive breast cancer and strategies for combating resistance.

Authors:  Simak Ali; R Charles Coombes
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

6.  RET/PTC oncogene activation is an early event in thyroid carcinogenesis.

Authors:  G Viglietto; G Chiappetta; F J Martinez-Tello; F H Fukunaga; G Tallini; D Rigopoulou; R Visconti; A Mastro; M Santoro; A Fusco
Journal:  Oncogene       Date:  1995-09-21       Impact factor: 9.867

7.  RET, ROS1 and ALK fusions in lung cancer.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Ritsuro Suzuki; Seiji Sakata; Satoko Hatano; Reimi Asaka; Wakako Hamanaka; Hironori Ninomiya; Hirofumi Uehara; Young Lim Choi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440

8.  The landscape of cancer genes and mutational processes in breast cancer.

Authors:  Philip J Stephens; Patrick S Tarpey; Helen Davies; Peter Van Loo; Chris Greenman; David C Wedge; Serena Nik-Zainal; Sancha Martin; Ignacio Varela; Graham R Bignell; Lucy R Yates; Elli Papaemmanuil; David Beare; Adam Butler; Angela Cheverton; John Gamble; Jonathan Hinton; Mingming Jia; Alagu Jayakumar; David Jones; Calli Latimer; King Wai Lau; Stuart McLaren; David J McBride; Andrew Menzies; Laura Mudie; Keiran Raine; Roland Rad; Michael Spencer Chapman; Jon Teague; Douglas Easton; Anita Langerød; Ming Ta Michael Lee; Chen-Yang Shen; Benita Tan Kiat Tee; Bernice Wong Huimin; Annegien Broeks; Ana Cristina Vargas; Gulisa Turashvili; John Martens; Aquila Fatima; Penelope Miron; Suet-Feung Chin; Gilles Thomas; Sandrine Boyault; Odette Mariani; Sunil R Lakhani; Marc van de Vijver; Laura van 't Veer; John Foekens; Christine Desmedt; Christos Sotiriou; Andrew Tutt; Carlos Caldas; Jorge S Reis-Filho; Samuel A J R Aparicio; Anne Vincent Salomon; Anne-Lise Børresen-Dale; Andrea L Richardson; Peter J Campbell; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

9.  Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.

Authors:  Jessica Kao; Keyan Salari; Melanie Bocanegra; Yoon-La Choi; Luc Girard; Jeet Gandhi; Kevin A Kwei; Tina Hernandez-Boussard; Pei Wang; Adi F Gazdar; John D Minna; Jonathan R Pollack
Journal:  PLoS One       Date:  2009-07-03       Impact factor: 3.240

10.  Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.

Authors:  Philip M Spanheimer; Jung-Min Park; Ryan W Askeland; Mikhail V Kulak; George W Woodfield; James P De Andrade; Anthony R Cyr; Sonia L Sugg; Alexandra Thomas; Ronald J Weigel
Journal:  Clin Cancer Res       Date:  2014-02-13       Impact factor: 12.531

View more
  5 in total

1.  Comprehensive immunohistochemical analysis of RET, BCAR1, and BCAR3 expression in patients with Luminal A and B breast cancer subtypes.

Authors:  Ana Carolina Pavanelli; Flavia Rotea Mangone; Piriya Yoganathan; Simone Aparecida Bessa; Suely Nonogaki; Cynthia A B de Toledo Osório; Victor Piana de Andrade; Iberê Cauduro Soares; Evandro Sobrosa de Mello; Lois M Mulligan; Maria Aparecida Nagai
Journal:  Breast Cancer Res Treat       Date:  2022-01-15       Impact factor: 4.872

2.  Super-enhancer-controlled positive feedback loop BRD4/ERα-RET-ERα promotes ERα-positive breast cancer.

Authors:  Zao-Zao Zheng; Lin Xia; Guo-Sheng Hu; Jun-Yi Liu; Ya-Hong Hu; Yu-Jie Chen; Jia-Yin Peng; Wen-Juan Zhang; Wen Liu
Journal:  Nucleic Acids Res       Date:  2022-10-14       Impact factor: 19.160

Review 3.  RET Gene Fusions in Malignancies of the Thyroid and Other Tissues.

Authors:  Massimo Santoro; Marialuisa Moccia; Giorgia Federico; Francesca Carlomagno
Journal:  Genes (Basel)       Date:  2020-04-15       Impact factor: 4.096

4.  A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer.

Authors:  Philip M Spanheimer; Amani Bashir; Allison W Lorenzen; Anna C Beck; Junlin Liao; Ingrid M Lizarraga; Lillian M Erdahl; Sonia L Sugg; Mark W Karwal; Ronald J Weigel
Journal:  Am J Clin Oncol       Date:  2021-09-01       Impact factor: 2.787

5.  Aberrant RET expression affects normal mammary gland post-lactation transition, enhancing cancer potential.

Authors:  Sabrina A Vallone; Martín García Solá; Carolina Schere-Levy; Roberto P Meiss; Gladys N Hermida; Lewis A Chodosh; Edith C Kordon; Nancy E Hynes; Albana Gattelli
Journal:  Dis Model Mech       Date:  2022-03-29       Impact factor: 5.732

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.